teaser
Pfizer’s Xiapex has gained approval from the European Commission for the treatment of a potentially disabling condition of the hand called Dupuytren’s contracture.
The tendons of patients affected by Dupuytren’s contracture tend to be shorter and thicker than those of healthy individuals, causing their fingers to curve inwards.
↓Article continues below this sponsored advert↓
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
↑Advertisement↑
Pfizer has the marketing rights to sell Xiapex – the first injectable treatment approved by Europe for Dupuytren’s contracture – throughout Europe.
The treatment will reach some European markets by the end of the year.
Pfizer 2011
